Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and reduces hyper‑excitability. It also binds to CRMP2 protein, further modulating neuronal activity and helping to prevent seizure propagation.

The specific dose of lacosamide is individualized by the prescribing clinician based on the patient’s clinical condition, response, and any relevant laboratory values. Healthcare providers determine the appropriate infusion rate and total daily amount.

Safety data for lacosamide during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, which may result in a different side‑effect profile and lower risk of certain drug‑drug interactions. Both classes are effective, but choice depends on individual patient factors and tolerability.

Lacosamide Fresenius Kabi must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use if the solution appears discolored or contains particles.

The medication is given by intravenous infusion. The infusion rate and duration are determined by the prescribing clinician, typically administered over a period of 15 minutes to several hours, depending on the therapeutic protocol and patient tolerance.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and emergence or worsening of suicidal thoughts or behaviors. Patients should be monitored closely for these events, especially during treatment initiation and dose adjustments.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe renal impairment, or a history of psychiatric illness associated with suicidal behavior.